menu ☰
menu ˟

Bird Rock Bio completes nimacimab phase 1 final patient visit for NAFLD

13 Sep 2018
Bird Rock Bio completed its final patient visit in a phase 1b ascending dose trial of nimacimab for treating patients with nonalcoholic fatty liver disease and diabetes or pre-diabetes, according to a press release.“The primary objectives of the mu...

Click here to view the full article which appeared in Hepatology

IPH Logo